COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Kirkby, Nicholas S ^a,b   Lundberg, Martina H ^a,b   Wright, William R ^a   Warner, Timothy D ^b   Paul Clark, Mark J ^a   Mitchell, Jane A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTACYCLIN; TRANSCRIPTOME; APOLIPOPROTEIN E; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROTECTIVE AGENT; PTGS2 PROTEIN, MOUSE; RGL1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; HEART PROTECTION; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RGL1 GENE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; T LYMPHOCYTE; ANIMAL; BLOOD VESSEL; C57BL MOUSE; DEFICIENCY; ENZYMOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; UPREGULATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD VESSELS; CYCLOOXYGENASE 2; EPOPROSTENOL; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; MALE; MICE, INBRED C57BL; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTOME; UP-REGULATION;

EID: 84902324508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098165     Document Type: Article

References (52)

1. Mitchell JA, Warner TD (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature reviews Drug discovery 5: 75-86.
2. Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. The New England journal of medicine 340: 1888-1899. (Pubitemid 29272670)
3. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, et al. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America 96: 7563-7568. (Pubitemid 29299702)
4. Wallace JL, McKnight W, Reuter BK, Vergnolle N (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119: 706-714.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine 343: 1520-1528, 1522 p following 1528.
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England journal of medicine 352: 1092-1102. (Pubitemid 40365350)
7. Warner TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371: 270-273.
8. Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. Journal of cardiovascular pharmacology 50: 470-479. (Pubitemid 350146448)
9. Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H, Hwa J (2011) NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PloS one 6: e16780.
10. McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS medicine 8: e1001098.
11. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, et al. (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. The Journal of clinical investigation 116: 1391-1399.
12. Barbieri SS, Amadio P, Gianellini S, Tarantino E, Zacchi E, et al. (2012) Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 126: 1373-1384.
13. Yu Z, Crichton I, Tang SY, Hui Y, Ricciotti E, et al. (2012) Disruption of the 5- lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proceedings of the National Academy of Sciences of the United States of America 109: 6727-6732.
14. Gitlin JM, Loftin CD (2009) Cyclooxygenase-2 inhibition increases lipopolysac-charide-induced atherosclerosis in mice. Cardiovascular research 81: 400-407.
15. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, et al. (2003) Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. Journal of the American College of Cardiology 41: 1812-1819. (Pubitemid 36584257)
16. Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, et al. (2007) A novel anti-atherogenic role for COX-2-potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins & other lipid mediators 84: 24-33. (Pubitemid 47069931)
17. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 98: 3358-3363. (Pubitemid 32220850)
18. Belton OA, Duffy A, Toomey S, Fitzgerald DJ (2003) Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108: 3017-3023. (Pubitemid 37553572)
19. Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, et al. (2002) No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scandinavian cardiovascular journal : SCJ 36: 362-367. (Pubitemid 36131423)
20. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, et al. (2005) Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111: 334-342. (Pubitemid 40165341)
21. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, et al. (2002) Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105: 1816-1823. (Pubitemid 34408892)
22. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, et al. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America 96: 272-277. (Pubitemid 29036089)
23. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. The Journal of clinical investigation 116: 4-15. (Pubitemid 43121782)
24. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, et al. (2012) Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proceedings of the National Academy of Sciences of the United States of America 109: 17597-17602.
25. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, et al. (2006) Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20: 2468-2475.
26. Liu B, Luo W, Zhang Y, Li H, Zhu N, et al. (2012) Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Experimental physiology 97: 277-289.
27. Liu B, Zhang Y, Zhu N, Li H, Luo W, et al. (2013) A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries. Am J Physiol Renal Physiol 305: F1315-1322.
28. Zhou Y, Luo W, Zhang Y, Li H, Huang D, et al. (2013) Cyclooxygenase-1 or -2- mediated metabolism of arachidonic acid in endothelium-dependent contraction of mouse arteries. Experimental physiology.
29. Flavahan NA (2007) Balancing prostanoid activity in the human vascular system. Trends in pharmacological sciences 28: 106-110.
30. Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, et al. (2013) LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PloS one 8: e69524.
31. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, et al. (2002) Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160: 49-58. (Pubitemid 34082716)
32. Stemme V, Swedenborg J, Claesson H, Hansson GK (2000) Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20: 146-152.
33. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, et al. (1999) Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriosclerosis, thrombosis, and vascular biology 19: 646-655. (Pubitemid 29135167)
34. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, et al. (2002) Cyclooxygenase-2 in human pathological disease. Advances in experimental medicine and biology 507: 177-184. (Pubitemid 37330179)
35. Gryglewski RJ, Dembinska-Kiec A, Zmuda A, Gryglewska T (1978) Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 31: 385-394. (Pubitemid 9066753)
36. Mehta JL, Lawson D, Mehta P, Saldeen T (1988) Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 85: 4511-4515.
37. Mattsson E, Brunkwall J, Falt K, Bergqvist D (1993) Prostanoid release immediately after balloon angioplasty in three models of atherosclerosis in rabbits. The European journal of surgery = Acta chirurgica 159: 15-21.
38. Wong E, Huang JQ, Tagari P, Riendeau D (2001) Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157: 393-402. (Pubitemid 32710018)
39. Tang SY, Monslow J, Todd L, Lawson J, Pure E, et al. (2014) Cyclooxygenase-2 in Endothelial and Vascular Smooth Muscle Cells Restrains Atherogenesis in Hyperlipidemic Mice. Circulation.
40. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482.
41. Kirkby NS, Low L, Seckl JR, Walker BR, Webb DJ, et al. (2011) Quantitative 3- dimensional imaging of murine neointimal and atherosclerotic lesions by optical projection tomography. PloS one 6: e16906.
42. Johnson J, Carson K, Williams H, Karanam S, Newby A, et al. (2005) Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 111: 1422-1430. (Pubitemid 40396809)
43. Chan ES, Zhang H, Fernandez P, Edelman SD, Pillinger MH, et al. (2007) Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 9: R4.
44. Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, et al. (2007) Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arteriosclerosis, thrombosis, and vascular biology 27: 2392-2399. (Pubitemid 350203955)
45. De Beer MC, Wroblewski JM, Noffsinger VP, Rateri DL, Howatt DA, et al. (2014) Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arteriosclerosis, thrombosis, and vascular biology 34: 255-261.
46. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, et al. (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115: 1634-1642. (Pubitemid 46648649)
47. Kirkby NS, Chan MV, Lundberg MH, Massey KA, Edmands WM, et al. (2013) Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27: 3938-3946.
48. Tilley SL, Coffman TM, Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. The Journal of clinical investigation 108: 15-23. (Pubitemid 32634916)
49. Rocca B, Maggiano N, Habib A, Petrucci G, Gessi M, et al. (2002) Distinct expression of cyclooxygenase-1 and -2 in the human thymus. European journal of immunology 32: 1482-1492. (Pubitemid 34546277)
50. Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, et al. (2010) Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 121: 2654-2660.
51. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, et al. (1999) Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. The Journal of clinical investigation 103: 1469-1477. (Pubitemid 29535503)
52. Neel NF, Martin TD, Stratford JK, Zand TP, Reiner DJ, et al. (2011) The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes Cancer 2: 275-287.